Form 4: BIODESIX CEO Hutton Reports RSU Vesting, Tax-Related Stock Sale
Insider Transaction Report
BIODESIX President and CEO Scott Hutton reported the vesting of restricted stock units and a subsequent tax-related sale of common stock.
Summary
- Scott Hutton, President & CEO and Director of BIODESIX INC (BDSX), reported changes in beneficial ownership.
- On February 20, 2026, 4,844 shares of Common Stock were acquired through the vesting of Restricted Stock Units (RSUs).
- On February 23, 2026, 1,490 shares of Common Stock were sold at a weighted average price of $12.7756 per share.
- This sale was automatically executed to cover taxes incurred upon the vesting of the RSUs.
- Following these transactions, Hutton beneficially owns 48,767 shares of Common Stock directly.
- Hutton also holds 14,531 Restricted Stock Units (RSUs) that vest in four equal annual installments from February 20, 2025.
- All reported numbers have been adjusted to reflect a one-for-twenty reverse stock split effective September 15, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing a routine compensation-related transaction for an executive, with no significant positive or negative implications for the company's operational or financial outlook.
Positives
- The vesting of 4,844 Restricted Stock Units represents a form of compensation for President & CEO Scott Hutton, aligning his interests with shareholders.
- The continued holding of 14,531 unvested Restricted Stock Units demonstrates ongoing long-term equity incentive for the executive.
Negatives
- The sale of 1,490 shares of common stock, even for tax purposes, represents a reduction in the insider's direct equity holding.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
StockSavvy.ai notes that routine insider transactions, such as those related to RSU vesting and subsequent tax-related sales, are common occurrences in publicly traded companies. These transactions typically reflect pre-planned compensation structures rather than discretionary trading based on new material information.
Stakeholder Impact
- Shareholders: The transaction is a routine insider compensation event and tax-related sale, which typically has minimal direct impact on existing shareholders. The executive's continued equity holdings align interests.
- Employees: The RSU vesting and tax sale are part of a standard executive compensation package, which may set a precedent for other equity-compensated employees.
Key Dates
| Date | Description |
|---|---|
| 09/15/2025 | Effective date of the one-for-twenty reverse stock split. |
| 02/20/2025 | Start date for the four successive equal annual installments of RSU vesting. |
| 02/20/2026 | Date of RSU vesting and acquisition of 4,844 shares of Common Stock. |
| 02/23/2026 | Date of sale of 1,490 shares of Common Stock to cover taxes. |
Recommendation
holdThis Form 4 details a routine insider transaction involving the vesting of restricted stock units and a subsequent tax-related sale. Such transactions are typically pre-scheduled and do not reflect a change in the company's fundamental outlook or the insider's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
BIODESIX, BDSX, Scott Hutton, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.